JP2022500392A5 - - Google Patents

Info

Publication number
JP2022500392A5
JP2022500392A5 JP2021513407A JP2021513407A JP2022500392A5 JP 2022500392 A5 JP2022500392 A5 JP 2022500392A5 JP 2021513407 A JP2021513407 A JP 2021513407A JP 2021513407 A JP2021513407 A JP 2021513407A JP 2022500392 A5 JP2022500392 A5 JP 2022500392A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
solvate
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021513407A
Other languages
English (en)
Japanese (ja)
Other versions
JP7554739B2 (ja
JP2022500392A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/051603 external-priority patent/WO2020061113A1/en
Publication of JP2022500392A publication Critical patent/JP2022500392A/ja
Publication of JP2022500392A5 publication Critical patent/JP2022500392A5/ja
Application granted granted Critical
Publication of JP7554739B2 publication Critical patent/JP7554739B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021513407A 2018-09-18 2019-09-17 ファルネソイドx受容体アゴニストおよびその使用 Active JP7554739B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862733004P 2018-09-18 2018-09-18
US201862733006P 2018-09-18 2018-09-18
US62/733,004 2018-09-18
US62/733,006 2018-09-18
US201962881560P 2019-08-01 2019-08-01
US62/881,560 2019-08-01
PCT/US2019/051603 WO2020061113A1 (en) 2018-09-18 2019-09-17 Farnesoid x receptor agonists and uses thereof

Publications (3)

Publication Number Publication Date
JP2022500392A JP2022500392A (ja) 2022-01-04
JP2022500392A5 true JP2022500392A5 (cg-RX-API-DMAC7.html) 2022-09-27
JP7554739B2 JP7554739B2 (ja) 2024-09-20

Family

ID=69887982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021513407A Active JP7554739B2 (ja) 2018-09-18 2019-09-17 ファルネソイドx受容体アゴニストおよびその使用

Country Status (27)

Country Link
US (4) US11084817B2 (cg-RX-API-DMAC7.html)
EP (2) EP3852748B1 (cg-RX-API-DMAC7.html)
JP (1) JP7554739B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250073553A (cg-RX-API-DMAC7.html)
CN (1) CN113056271B (cg-RX-API-DMAC7.html)
AU (2) AU2019344903B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004919A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112411A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000632A1 (cg-RX-API-DMAC7.html)
DK (1) DK3852748T3 (cg-RX-API-DMAC7.html)
ES (1) ES3051007T3 (cg-RX-API-DMAC7.html)
FI (1) FI3852748T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251321T1 (cg-RX-API-DMAC7.html)
IL (1) IL281475B2 (cg-RX-API-DMAC7.html)
LT (1) LT3852748T (cg-RX-API-DMAC7.html)
MA (1) MA53665B1 (cg-RX-API-DMAC7.html)
MD (1) MD3852748T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021003110A (cg-RX-API-DMAC7.html)
PH (1) PH12021550605A1 (cg-RX-API-DMAC7.html)
PL (1) PL3852748T3 (cg-RX-API-DMAC7.html)
PT (1) PT3852748T (cg-RX-API-DMAC7.html)
RS (1) RS67371B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102651SA (cg-RX-API-DMAC7.html)
SI (1) SI3852748T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600076T1 (cg-RX-API-DMAC7.html)
TW (1) TWI833805B (cg-RX-API-DMAC7.html)
WO (1) WO2020061113A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018236275B2 (en) 2017-03-15 2022-05-12 Eli Lilly And Company Farnesoid X receptor agonists and uses thereof
DK3596053T3 (da) 2017-03-15 2023-09-25 Organovo Inc Farnesoid-x-receptoragonister og anvendelser deraf
EP3852748B1 (en) 2018-09-18 2025-09-03 Eli Lilly and Company Farnesoid x receptor agonists and uses thereof
IL293892A (en) 2020-01-15 2022-08-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Use of fxr agonists for treating an infection by hepatitis d virus
CN120227340A (zh) * 2020-03-18 2025-07-01 伊莱利利公司 法尼醇x受体激动剂的制剂
KR20220154801A (ko) * 2020-03-18 2022-11-22 메타크린, 인크. 질환의 치료를 위한 파르네소이드 x 수용체 작용제
JP7664278B2 (ja) * 2020-03-18 2025-04-17 オルガノボ,インク. ファルネソイドx受容体アゴニストの結晶質形態
MX2023008365A (es) 2021-01-14 2023-10-04 Enyo Pharma Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv.
TW202308629A (zh) 2021-04-28 2023-03-01 法商Enyo製藥公司 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效
CN116554121A (zh) * 2023-05-05 2023-08-08 济南悟通生物科技有限公司 一种2-异丁基噻唑的合成方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4537900A (en) 1999-05-17 2000-12-05 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
EP1187810A2 (en) 1999-05-25 2002-03-20 Sepracor, Inc. Heterocyclic analgesic compounds and their use
US6511980B2 (en) 2000-05-05 2003-01-28 Ortho Mcneil Pharmaceutical, Inc. Substituted diamine derivatives useful as motilin antagonists
WO2001092226A1 (en) 2000-05-25 2001-12-06 Sepracor, Inc. Heterocyclic analgesic compounds and method of use thereof
HUP0303360A2 (hu) 2000-09-25 2004-01-28 Actelion Pharmaceuticals Ltd. Maláriaellenes hatású szubsztituált amino-aza-cikloalkánok és ezeket tartalmazó gyógyszerkészítmények
FR2815032B1 (fr) 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
FR2825706B1 (fr) 2001-06-06 2003-12-12 Pf Medicament Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase
FR2839974B1 (fr) 2002-05-24 2004-07-16 Pf Medicament Derives de phenyl-furane ou de phenyl-thiophene,leur preparation et leur application a titre de medicament
WO2004009549A2 (en) 2002-07-18 2004-01-29 Actelion Pharmaceuticals Ltd Piperidines useful for the treatment of central nervous system disorders
MXPA05003054A (es) 2002-09-20 2005-05-27 Pfizer Prod Inc Ligandos de amida y sulfonamida para el receptor de estrogenos.
AU2003290796A1 (en) 2002-11-14 2004-06-15 The Scripps Research Institute Non-steroidal fxr agonists
WO2004046323A2 (en) 2002-11-15 2004-06-03 The Salk Institute For Biological Studies Structure of the farnesoid x receptor ligand binding domain and methods of use therefor
US20050143449A1 (en) 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
GB0309781D0 (en) 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
US7754711B2 (en) 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
EP2316827B1 (en) 2003-07-30 2016-01-27 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
WO2005058822A1 (en) 2003-12-17 2005-06-30 Actelion Pharmaceuticals Ltd Substituted amino-cycloalkanes
JP2007530582A (ja) 2004-03-26 2007-11-01 ライジェル ファーマシューティカルズ, インコーポレイテッド 代謝可能部分を含む複素環抗ウイルス化合物およびその使用
US20050272784A1 (en) 2004-05-07 2005-12-08 Xiaobing Li Inhibitors of bacterial Type III protein secretion systems
JP2006199656A (ja) 2005-01-24 2006-08-03 Kowa Co アミド基を有する環状アミン化合物
MY144229A (en) 2006-01-26 2011-08-15 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use as therapeutic agents
CA2644369A1 (en) 2006-03-28 2007-10-04 Novartis Ag Amide derivatives and their application for the treatment of g protein related diseases
US20080081824A1 (en) 2006-09-29 2008-04-03 Bristol-Myers Squibb Company Substituted piperidines as modulators of chemokine receptor activity
WO2008065500A2 (en) 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
EP2234977A4 (en) 2007-12-19 2011-04-13 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
WO2010001869A1 (ja) 2008-06-30 2010-01-07 武田薬品工業株式会社 4置換ベンゼン化合物およびその用途
JP2010077109A (ja) 2008-08-28 2010-04-08 Takeda Chem Ind Ltd 複素環化合物およびその用途
US8435980B2 (en) 2009-07-15 2013-05-07 Abbvie Inc. Pyrrolopyridine inhibitors of kinases
AU2010272523A1 (en) 2009-07-15 2012-02-02 Merck Serono S.A. Tetrazole derivatives
FR2963005B1 (fr) 2010-07-23 2012-08-17 Sanofi Aventis Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique
ME02754B (me) 2011-03-23 2018-01-20 Trevena Inc Ligandi opioidnih receptora i postupci njihove upotrebe i pripreme
WO2013008706A1 (ja) 2011-07-13 2013-01-17 エム・テクニック株式会社 結晶子径を制御された微粒子の製造方法
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
RU2543485C2 (ru) 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
GB201316824D0 (en) 2013-09-23 2013-11-06 R & D Vernalis Ltd New Chemical Entities
JP2017511304A (ja) 2014-03-13 2017-04-20 ソーク インスティチュート フォー バイオロジカル スタディーズ フェキサラミン類似体ならびに作製方法および使用方法
CA2942403A1 (en) 2014-03-13 2015-09-17 Salk Institute For Biological Studies Fxr agonists and methods for making and using
US10077268B2 (en) 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
US20150258052A1 (en) 2014-03-13 2015-09-17 Salk Institute For Biological Studies Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissue
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
US20180116993A1 (en) 2015-01-22 2018-05-03 Xiamen University Modulators of farnesoid x receptor and methods for the use thereof
AU2016233579A1 (en) 2015-03-13 2017-10-12 Salk Institute For Biological Studies Treating latent autoimmune diabetes of adults with farnesoid X receptor agonists to activate intestinal receptors
WO2017018751A1 (ko) 2015-07-24 2017-02-02 동국대학교 산학협력단 Blt 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물
EP3350166A4 (en) * 2015-09-16 2019-05-01 Metacrine, Inc. FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF
EP3350165B1 (en) 2015-09-16 2023-07-26 Organovo, Inc. Farnesoid x receptor agonists and uses thereof
WO2017049176A1 (en) * 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
US10626081B2 (en) 2015-09-16 2020-04-21 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
CN105477636B (zh) * 2015-10-16 2019-09-17 厦门大学 使用阿维菌素及其衍生物治疗代谢疾病的方法
CN107126419B (zh) 2016-02-26 2020-06-19 石药集团中诺药业(石家庄)有限公司 一种奥贝胆酸片剂及其制备方法
KR102316645B1 (ko) 2016-03-31 2021-10-25 가부시키가이샤 아데카 감광성 조성물 및 신규 화합물
WO2018170173A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
DK3596053T3 (da) 2017-03-15 2023-09-25 Organovo Inc Farnesoid-x-receptoragonister og anvendelser deraf
AU2018236275B2 (en) 2017-03-15 2022-05-12 Eli Lilly And Company Farnesoid X receptor agonists and uses thereof
US20200131132A1 (en) 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2018170165A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
CZ2017298A3 (cs) 2017-05-26 2018-12-05 Zentiva, K.S. Amorfní formy obeticholové kyseliny
WO2020060007A1 (ko) 2018-09-17 2020-03-26 엘지전자 주식회사 5g 이동통신에서 pdu 세션을 핸들링하는 방법 및 무선 기기
US20220047553A1 (en) 2018-09-18 2022-02-17 Metacrine, Inc. Farnesoid x receptor agonists for the treatment of disease
BR112021004931A2 (pt) 2018-09-18 2021-06-01 Metacrine, Inc. formas cristalinas de um agonista de receptor farnesoide x
CN113056264A (zh) 2018-09-18 2021-06-29 梅塔科林公司 法尼醇x受体激动剂及其用途
WO2020061116A1 (en) 2018-09-18 2020-03-26 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2020061117A1 (en) 2018-09-18 2020-03-26 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
EP3852748B1 (en) 2018-09-18 2025-09-03 Eli Lilly and Company Farnesoid x receptor agonists and uses thereof
WO2020061118A1 (en) 2018-09-18 2020-03-26 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
JP7664278B2 (ja) 2020-03-18 2025-04-17 オルガノボ,インク. ファルネソイドx受容体アゴニストの結晶質形態
CN120227340A (zh) 2020-03-18 2025-07-01 伊莱利利公司 法尼醇x受体激动剂的制剂
KR20220154801A (ko) 2020-03-18 2022-11-22 메타크린, 인크. 질환의 치료를 위한 파르네소이드 x 수용체 작용제

Similar Documents

Publication Publication Date Title
JP2020514333A5 (cg-RX-API-DMAC7.html)
JP2014524472A5 (cg-RX-API-DMAC7.html)
ES2546063T3 (es) Agentes de enlace a amiloides
JP2009084270A5 (cg-RX-API-DMAC7.html)
TWI591047B (zh) 巨大戟萜醇-3-醯化物iii及巨大戟萜醇-3-胺基甲酸酯化物
JP2021534124A5 (cg-RX-API-DMAC7.html)
JP2022533069A5 (cg-RX-API-DMAC7.html)
JP2010512342A5 (cg-RX-API-DMAC7.html)
JP2019518071A (ja) Nlrp活性に関連する状態を処置するための化合物および組成物
JP2011523412A5 (cg-RX-API-DMAC7.html)
JP2009507896A5 (cg-RX-API-DMAC7.html)
JP2021527638A5 (cg-RX-API-DMAC7.html)
JP2018188478A (ja) 肝疾患を処置する方法
RU2016137832A (ru) Соединения для лечения опосредованных комплементом нарушений
JP2014511891A5 (cg-RX-API-DMAC7.html)
RU2015105262A (ru) Азотсодержащие гетероциклические производные и их применение в фармацевтических препаратах
JP2017512186A5 (cg-RX-API-DMAC7.html)
JP2006515838A5 (cg-RX-API-DMAC7.html)
JP2009530424A5 (cg-RX-API-DMAC7.html)
JP2020529994A5 (cg-RX-API-DMAC7.html)
JP2010501584A5 (cg-RX-API-DMAC7.html)
JP2007504284A5 (cg-RX-API-DMAC7.html)
RU2011129856A (ru) Схема приема агониста рецептора s1p
JP2013508279A5 (cg-RX-API-DMAC7.html)
RU2014111055A (ru) 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение